[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359090-105":59,"doc-detail-359090-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunogenicity-of-neoantigens-from-hepatocellular-carcinoma-patients-treated-with-a-combined-radioimmunotherapy","Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy","","In the NASIR-HCC trial, hepatocellular carcinoma patients treated with selective internal radiation therapy and the anti-PD-1 antibody Nivolumab showed limited clinical benefit for many participants. This study evaluated neoantigen (neoAg)-specific immunity in patients without benefit, testing predicted neoAgs in vitro and immunizing HLA transgenic mice in vivo. NeoAg-specific responses were detected in both groups, and polyepitopic peptide vaccination induced stronger T-cell responses than a polyepitopic DNA vaccine.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunogenicity-of-neoantigens-from-hepatocellular-carcinoma-patients-treated-with-a-combined-radioimmunotherapy/359090/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunogenicity-of-neoantigens-from-hepatocellular-carcinoma-patients-treated-with-a-combined-radioimmunotherapy/359090.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical context motivated this study?","Question",{"text":112,"@type":113},"Patients with hepatocellular carcinoma in the NASIR-HCC trial received SIRT and nivolumab, but many did not achieve clinical benefit, prompting investigation of neoAg-based vaccination potential.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were neoantigens and immune reactivity assessed?",{"text":117,"@type":113},"Predicted neoAgs from patients were tested for immune reactivity in vitro, and immunogenicity was further evaluated using HLA transgenic HHD-DR1 mice with predicted neoAgs.",{"name":119,"@type":110,"acceptedAnswer":120},"Which vaccination strategy produced stronger T-cell responses?",{"text":121,"@type":113},"A polyepitopic peptide vaccination containing neoAgs from a non-benefit patient induced stronger and broader T-cell responses than a polyepitopic DNA vaccine.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359090,1792175173,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","BRIEF REPORT  \nImmunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy  \nBelén Aparicioa, b, Leyre Silvaa, b, Marta Ruiza, b , Diana Llópiza, b , David Repáraza, b, Patrick Theunissena, b,c, Ibon Tamayoa, b, Josune Egeaa, b, Ana Igeab,c, Cristian Smerdoub,c , Maria Peñasd, Cristina Perpiñád, Ana Matillae,f, María Varelag, Maria Reigf, h ,  \nManuel de la Torre-Alaezf, i , Josepmaria Argemíb,c,f, i , Bruno Sangrob,f, i , Sandra Hervás-Stubbsa, b,f  and Pablo Sarobea, b,f   \naImmunology and Immunotherapy Program, Cancer Center Clínica Universidad de Navarra (CCUN) Pamplona, Pamplona, Spain; bIdiSNA, Pamplona, Spain; cDNA and RNA Medicine Division, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN) Pamplona, Pamplona, Spain; dRecombina Biotech, Mutilva, Spain; eDigestive Diseases Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; fCIBEREHD, Spain; gLiver Unit, Hospital Universitario Central de Asturias, IUOPA, ISPA, FINBA, Universidad de Oviedo, Oviedo, Spain; hBCLC group, Liver Unit, ICMDM, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain; iLiver Unit and HPB Oncology Area, Clínica Universidad de Navarra, Pamplona, Spain  \nABSTRACT  \nIn some cancers, patients responding to immune checkpoint inhibitors (ICI) usually harbor tumors with a higher tumor mutational burden and increased lymphocyte infiltration targeting mutation-derived neoantigens (neoAgs) . In the NASIR-HCC trial, patients with hepatocellular carcinoma (HCC) received selective internal radiation therapy and the anti-PD-1 antibody Nivolumab, but many of them did not achieve clinical benefit (B). Since neoAg-based vaccination could enhance tumor infiltration and ICI responses, we studied neoAg-specific immunity in these patients and assessed whether patients with no benefit (NB) harbored sufficient immunogenic neoAgs for therapeutic vaccination. Using predicted neoAgs from 6 B and 4 NB patients, we tested immune reactivity in vitro. NeoAg-specific responses were detected in 75% of B and 83% of NB patients, recognizing 37% and 63% of neoAgs tested, respectively. In vivo immunization experiments in HLA transgenic HHD-DR1 mice using HLA-A*02.01- or HLA-DRB1*01-predicted neoAgs from four NB patients revealed responses against most neoAgs (87% and 73%, respectively), expanding the repertoire of immunogenic epitopes. Finally, polyepitopic peptide vaccination containing neoAgs from an NB patient induced stronger and broader T-cell responses compared to polyepitopic DNA vaccine. Our results demonstrate the immunogenicity of neoAgs in our cohort, supporting their potential utility in therapeutic vaccines designed to boost antitumor immunity.  \nARTICLE HISTORY  \nReceived 25 September 2025 Revised 2 February 2026 Accepted 9 March 2026  \nKEYWORDS  \nHepatocellular carcinoma; neoantigens;  \nimmunotherapy; polyepitopic vaccines; HLA transgenic mice  \nIntroduction  \nHepatocellular carcinoma (HCC), the dominant form of primary liver cancer, is the third cause of cancerrelated death worldwide.1 Immune checkpoint inhibitors (ICI) are used for the first-line treatment of patients with advanced HCC. However, even with currently approved combinations targeting programmed cell death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) or PD-L1/PD-1 and cytotoxic T lymphocyteassociated protein 4 (CTLA-4), only 20%–36% of patients have objective tumor responses.2-4 As in other malignancies, tumors containing a higher lymphocytic infiltrate have a higher probability to respond to ICI.5 Therefore, strategies directed to increasing tumor lymphocytic infiltration and promoting the response to ICI are needed. In the NASIR-HCC (CA209-992) clinical trial, HCC patients received selective internal radiation therapy (SIRT), which is known to generate cell death in the presence of inflammatory factors,6 and the antiPD-1 antibody Nivolumab, resulting in an overall respons","cbCaimMjhALkE18N","https://ap.wps.com/l/cbCaimMjhALkE18N","pdf",2400680,15,"English","# Abstract\n# Introduction","[{\"question\":\"What clinical context motivated this study?\",\"answer\":\"Patients with hepatocellular carcinoma in the NASIR-HCC trial received SIRT and nivolumab, but many did not achieve clinical benefit, prompting investigation of neoAg-based vaccination potential.\"},{\"question\":\"How were neoantigens and immune reactivity assessed?\",\"answer\":\"Predicted neoAgs from patients were tested for immune reactivity in vitro, and immunogenicity was further evaluated using HLA transgenic HHD-DR1 mice with predicted neoAgs.\"},{\"question\":\"Which vaccination strategy produced stronger T-cell responses?\",\"answer\":\"A polyepitopic peptide vaccination containing neoAgs from a non-benefit patient induced stronger and broader T-cell responses than a polyepitopic DNA vaccine.\"}]","Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy | PDF",1790136072,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a80a7eb192b16a9344f0dee36f8f7cbf.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4ec4aa325df88a7aed278979d14acf1.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65120706e73c00644f2da1f66d9124c7.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/824eb7908cc2baeaf7d26dc122fb1203.webp",980,1306]